Ionis Says Partner Roche Enrolls First Patient in Huntington's Disease Study
January 28 2019 - 8:08AM
Dow Jones News
By Michael Dabaie
Ionis Pharmaceuticals Inc. (IONS) said Monday its partner Roche
(RHHBY) enrolled the first patient in a pivotal study of RG6042 for
Huntington's disease.
With the initiation of the study, Ionis said it earned a $35
million milestone payment.
Roche and Ionis are collaborating to develop antisense drugs to
treat Huntington's disease. In total, Ionis has generated $135
million in up-front, milestone and license payments and is eligible
to receive additional milestone payments as RG6042 progresses in
development, as well as royalties.
Huntington's disease is a hereditary neurodegenerative disorder
for which there is currently no approved disease-modifying
treatment, Ionis said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 28, 2019 07:53 ET (12:53 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
